Biocytogen's Boston Facility Earns AAALAC Accreditation, Bolstering Preclinical Research Credentials
Event summary
- Biocytogen's Boston research facility received Full Accreditation from AAALAC International on June 15, 2026.
- The accreditation recognizes excellence in laboratory animal care and use, beyond regulatory requirements.
- Biocytogen's Boston facility supports drug discovery and translational research for global pharmaceutical partners.
- The company's BioMice™ platform offers comprehensive genetically engineered disease models across multiple therapeutic areas.
- Biocytogen has established over 350 agreements for therapeutic antibodies and clinical assets as of December 31, 2025.
The big picture
Biocytogen's AAALAC accreditation underscores its commitment to high standards in preclinical research, aligning with the growing industry emphasis on ethical and rigorous animal care. This move positions the company to better compete with other biotech service providers in the crowded drug discovery space, particularly as demand for reliable preclinical models and antibody discovery platforms continues to rise. The accreditation also comes at a time when regulatory scrutiny on animal welfare in research is increasing globally.
What we're watching
- Partnership Expansion
- How Biocytogen's AAALAC accreditation will influence its ability to attract and retain global pharmaceutical partners.
- Scientific Rigor
- Whether the accreditation will enhance the reliability of preclinical data generated by Biocytogen, reducing development risk for partners.
- Operational Excellence
- The pace at which Biocytogen can integrate the accreditation standards across its other global facilities.
Related topics